Changing causes of death in persons with haematological cancers 1975-2016
- PMID: 35577905
- PMCID: PMC9252904
- DOI: 10.1038/s41375-022-01596-z
Changing causes of death in persons with haematological cancers 1975-2016
Abstract
Causes of death in persons with haematological cancers include the index cancer, a new cancer or a seemingly unrelated cause such as cardio-vascular disease. These causes are complex and sometimes confounded. We analyzed trends in cause of death in 683,333 persons with an index haematological cancer diagnosed in 1975-2016 reported in the Surveillance, Epidemiology and End Results dataset. Non-cancer deaths were described using standardized mortality ratios. The index cancer was the predominant cause of death amongst persons with plasma cell myeloma, acute lymphoblastic leukaemia and acute myeloid leukaemia. Non-cancer death was the major cause of death in persons with chronic lymphocytic leukaemia, Hodgkin lymphoma and chronic myeloid leukaemia, mostly from cardio-vascular diseases. The greatest relative decrease in index-cancer deaths was amongst persons with Hodgkin lymphoma, chronic myeloid leukaemia and chronic lymphocytic leukaemia, where the proportion of non-cancer deaths increased substantially. Changing distribution of causes of death across haematological cancers reflects substantial progress in some cancers and suggests strategies to improve the survival of persons with haematological cancers in the future.
© 2022. The Author(s).
Conflict of interest statement
RPG is a Consultant to BeiGene Ltd., CStone Pharmaceuticals and Kite Pharmma; a Consultant to Fusion Pharma LLC, LaJolla NanoMedical Inc. and Mingsight Parmaceuticals Inc.; an Advisory Board member for Antegene Biotech LLC and StemRad Ltd; Medical Director at FFF Enterprises Inc; Partner in AZACA Inc; and on the Board of Directors of the Russian Foundation for Cancer Research Support.
Figures






Similar articles
-
The epidemiology of haematological cancers in Sarawak, Malaysia (1996 to 2015).BMC Cancer. 2023 Jun 19;23(1):563. doi: 10.1186/s12885-023-10988-y. BMC Cancer. 2023. PMID: 37337159 Free PMC article.
-
[Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004].Rev Epidemiol Sante Publique. 2009 Jun;57(3):151-8. doi: 10.1016/j.respe.2009.02.204. Epub 2009 Apr 17. Rev Epidemiol Sante Publique. 2009. PMID: 19375876 French.
-
Biannual report of the Cochrane Haematological Malignancies Group.J Natl Cancer Inst. 2004 Aug 4;96(15):E2. doi: 10.1093/jnci/djh242. J Natl Cancer Inst. 2004. PMID: 15292394 No abstract available.
-
A comprehensive approach to therapy of haematological malignancies in older patients.Lancet Haematol. 2021 Nov;8(11):e840-e852. doi: 10.1016/S2352-3026(21)00241-6. Epub 2021 Oct 5. Lancet Haematol. 2021. PMID: 34624238 Review.
-
Changing concepts in the management of leukaemia.Med J Aust. 1989 Jul 3;151(1):43-51. doi: 10.5694/j.1326-5377.1989.tb128454.x. Med J Aust. 1989. PMID: 2671615 Review. No abstract available.
Cited by
-
Hematologic cancers and infections: how to detect infections in advance and determine the type?Front Cell Infect Microbiol. 2024 Nov 4;14:1476543. doi: 10.3389/fcimb.2024.1476543. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39559703 Free PMC article. Review.
-
Cardiovascular Disease Mortality Risk among Long-term Survivors of Different Hodgkin Lymphoma Types.Rev Cardiovasc Med. 2025 Jun 30;26(6):24981. doi: 10.31083/RCM24981. eCollection 2025 Jun. Rev Cardiovasc Med. 2025. PMID: 40630442 Free PMC article.
-
Surgical resection for second primary colorectal cancer: a population-based study.Front Med (Lausanne). 2023 Jun 22;10:1167777. doi: 10.3389/fmed.2023.1167777. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37425303 Free PMC article.
-
Venous thromboembolism and mortality in patients with hematological malignancies.Bleeding Thromb Vasc Biol. 2024;3(Suppl 1):119. doi: 10.4081/btvb.2024.119. Epub 2024 May 16. Bleeding Thromb Vasc Biol. 2024. PMID: 39669477 Free PMC article.
-
A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors.Bioeng Transl Med. 2023 Nov 9;9(2):e10601. doi: 10.1002/btm2.10601. eCollection 2024 Mar. Bioeng Transl Med. 2023. PMID: 38435821 Free PMC article. Review.
References
-
- Global Burden of Disease Cancer C. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4:1553–68. doi: 10.1001/jamaoncol.2018.2706. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical